Phio Pharmaceuticals Corp. (PHIO) shareholders
PHIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.77−0.04 (-5.03%)
Close on Nov 13, 2026Market cap $8.96MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.6%
1M of 12M shares
Institutional holders
24
4 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
16 buys · 0 sales
Net bought $136.99K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Heights Capital Management, Inc. Joint filing with CVI Investments, Inc. (9.90%) | 1,194,719 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.10%), Intracoastal Capital LLC (9.10%) | 1,142,556 | 9.10% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PHIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 117,755 | 1.01% | $120.70K | −1,434 | 0.00% |
| Geode Capital Management, LLC | 114,574 | 0.99% | $117.44K | −32,680 | 0.00% |
| Vanguard Capital Management LLC | 94,262 | 0.81% | $96.62K | +14,409 | 0.00% |
| Nomura Asset Management International Inc. | 50,000 | 0.43% | $51.00K | New | 0.00% |
| Cetera Investment Advisers | 47,500 | 0.41% | $48.69K | +2,500 | 0.00% |
| Citadel Advisors LLC | 47,150 | 0.41% | $48.33K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 38,169 | 0.33% | $39.12K | – | 0.00% |
| Northern Trust Corp | 27,768 | 0.24% | $28.46K | +4,010 | 0.00% |
| Two Sigma Investments, LP | 21,501 | 0.19% | $22.04K | −10,994 | 0.00% |
| XTX Topco Ltd | 18,475 | 0.16% | $18.94K | −6,393 | 0.00% |
| Hrt Financial LP | 13,182 | 0.11% | $13.00K | −21,550 | 0.00% |
| Bridgeway Capital Management, LLC | 12,000 | 0.10% | $12.30K | New | 0.00% |
| Citigroup Inc | 11,605 | 0.10% | $11.90K | +10,580 | 0.00% |
| Captrust Financial Advisors | 10,000 | 0.09% | $10.25K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 6,206 | 0.05% | $6.36K | −1,414 | 0.00% |
| Morgan Stanley | 6,000 | 0.05% | $6.15K | – | 0.00% |
| UBS Group AG | 5,387 | 0.05% | $5.52K | −21,600 | 0.00% |
| Osaic Holdings, Inc. | 2,000 | 0.02% | $2.06K | – | 0.00% |
| Spire Wealth Management | 1,990 | 0.02% | $2.05K | −10 | 0.00% |
| SBI Securities Co., Ltd. | 1,247 | 0.01% | $1.28K | +23 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 24 | 1M | 5.6% | 4 / 6 | 8 / 4 | 0M | 0M |
| Q1 2026 | 24 | 1M | 5.8% | 14 / 5 | 0 / 6 | 0M | 0M |
| Q4 2025 | 17 | 0M | 3.1% | 8 / 5 | 0 / 2 | 0M | 0M |
| Q3 2025 | 11 | 0M | 1.6% | 3 / 4 | 1 / 3 | 0M | 0M |
| Q2 2025 | 11 | 0M | 1.4% | 4 / 3 | 1 / 4 | 0M | 0M |
| Q1 2025 | 11 | 0M | 0.9% | 3 / 4 | 3 / 3 | 0M | 0M |
| Q4 2024 | 11 | 0M | 1.3% | 7 / 2 | 0 / 2 | 0M | 0M |
| Q3 2024 | 6 | 0M | 0.2% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held PHIO in Q2 2026, 36% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PHIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 94,262 | 0.81% | $96.62K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 80,599 | 0.69% | $89.46K | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 50,000 | 0.43% | $51.25K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 14,664 | 0.13% | $16.28K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 13,285 | 0.11% | $14.75K | 0.00% | May 31, 2026 |
| Ultra-Small Company Fund | 12,000 | 0.10% | $12.30K | 0.01% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 4 | 0.00% | $4 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert J. Bitterman | Chairman, Pres. & CEO, Director | 789,871 | 6.80% | Nov 10, 2026 |
| Lisa Cabott Carson | Chief Financial Officer | 189,112 | 1.63% | Sep 29, 2026 |
| David H. Deming | Director | 49,800 | 0.43% | Nov 12, 2026 |
| Ronald Todd Plott | Director | 60,300 | 0.52% | Nov 10, 2026 |
| Patricia A. Bradford | Director | 64,151 | 0.55% | Sep 25, 2026 |
| Curtis Lockshin | Director | 35,155 | 0.30% | Feb 6, 2026 |
| Jonathan E. Freeman | Director | 32,655 | 0.28% | Feb 6, 2026 |
| Robert L. Ferrara | Director | 38,666 | 0.33% | Sep 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David H. Deming Director | Nov 11, 2026 | Buy | +5,200 | $0.84 | $4.36K | 49,800 |
| David H. Deming Director | Nov 10, 2026 | Buy | +6,800 | $0.84 | $5.71K | 44,600 |
| Ronald Todd Plott Director | Nov 9, 2026 | Buy | +18,300 | $0.83 | $15.19K | 60,300 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Nov 9, 2026 | Buy | +25,000 | $0.82 | $20.50K | 789,871 |
| Ronald Todd Plott Director | Sep 29, 2026 | Buy | +5,000 | $1.04 | $5.20K | 42,000 |
| Ronald Todd Plott Director | Sep 28, 2026 | Buy | +5,000 | $1.03 | $5.15K | 37,000 |
| Lisa Cabott Carson Chief Financial Officer | Sep 28, 2026 | Award | +108,000 | – | – | 189,112 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Sep 28, 2026 | Award | +400,000 | – | – | 764,871 |
| Ronald Todd Plott Director | Sep 28, 2026 | Award | +17,000 | – | – | 32,000 |
| Patricia A. Bradford Director | Sep 24, 2026 | Buy | +6,500 | $1.01 | $6.57K | 64,151 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Sep 22, 2026 | Buy | +2,000 | $1.03 | $2.06K | 364,871 |
| Patricia A. Bradford Director | Sep 15, 2026 | Buy | +12,000 | $1.03 | $12.36K | 57,651 |
| Lisa Cabott Carson Chief Financial Officer | Sep 11, 2026 | Tax withholding | −12,888 | $1.03 | $13.27K | 81,112 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Sep 11, 2026 | Tax withholding | −68,550 | $1.03 | $70.61K | 362,871 |
| Ronald Todd Plott Director | Aug 19, 2026 | Buy | +15,000 | $1.14 | $17.10K | 15,000 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Aug 18, 2026 | Buy | +10,000 | $1.06 | $10.60K | 431,421 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Jun 26, 2026 | Buy | +10,000 | $0.99 | $9.90K | 421,421 |
| Curtis Lockshin Director | Feb 5, 2026 | Award | +16,600 | – | – | 35,155 |
| Jonathan E. Freeman Director | Feb 5, 2026 | Award | +16,600 | – | – | 32,655 |
| Lisa Cabott Carson Chief Financial Officer | Feb 5, 2026 | Award | +47,000 | – | – | 94,000 |
| David H. Deming Director | Feb 5, 2026 | Award | +23,800 | – | – | 37,800 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Feb 5, 2026 | Award | +120,000 | – | – | 411,421 |
| Patricia A. Bradford Director | Feb 5, 2026 | Award | +18,500 | – | – | 45,651 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Dec 31, 2025 | Buy | +5,000 | $1.03 | $5.15K | 291,421 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Dec 23, 2025 | Buy | +5,000 | $1.02 | $5.10K | 286,421 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Nov 21, 2025 | Buy | +5,000 | $1.14 | $5.70K | 281,421 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Nov 18, 2025 | Buy | +5,000 | $1.27 | $6.35K | 276,421 |
| Patricia A. Bradford Director | Sep 11, 2025 | Award | +18,800 | – | – | 27,151 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Sep 11, 2025 | Award | +250,000 | – | – | 271,421 |
| Robert J. Bitterman Chairman, Pres. & CEO, Director | Sep 11, 2025 | Tax withholding | −4,111 | $2.32 | $9.54K | 21,421 |
| David H. Deming Director | Sep 11, 2025 | Award | +14,000 | – | – | 14,000 |
| Lisa Cabott Carson VP, Finance and Administration | Sep 11, 2025 | Award | +47,000 | – | – | 47,000 |
| Curtis Lockshin Director | Sep 11, 2025 | Award | +16,200 | – | – | 18,555 |
| Jonathan E. Freeman Director | Sep 11, 2025 | Award | +14,700 | – | – | 16,055 |
| Robert L. Ferrara Director | Sep 11, 2025 | Award | +23,000 | – | – | 38,666 |
| Robert L. Ferrara Director | Sep 11, 2025 | Award | +23,100 | – | – | 38,766 |
| Robert J. Bitterman Chairman, Pres & CEO, Director | Jun 10, 2025 | Buy | +2,000 | $2.42 | $4.84K | 27,149 |
| Robert L. Ferrara Director | Jun 10, 2025 | Buy | +2,500 | $2.42 | $6.05K | 15,666 |
| Robert J. Bitterman Chairman, Pres & CEO, Director | Jun 9, 2025 | Buy | +1,500 | $2.75 | $4.13K | 25,149 |
| Robert J. Bitterman Chairman, Pres & CEO, Director | May 22, 2025 | Buy | +1,200 | $1.78 | $2.14K | 23,649 |
| Robert J. Bitterman Chairman, Pres & CEO, Director | May 21, 2025 | Buy | +3,000 | $1.77 | $5.31K | 22,449 |
| Robert L. Ferrara Director | May 20, 2025 | Buy | +2,500 | $1.82 | $4.55K | 13,166 |
| Robert J. Bitterman Chairman, Pres & CEO, Director | Sep 11, 2024 | Award | +15,500 | – | – | 17,832 |
| Robert M. Infarinato VP, CFO | Sep 11, 2024 | Award | +3,000 | – | – | 11,000 |
| Jonathan E. Freeman Director | Sep 11, 2024 | Award | +1,000 | – | – | 1,000 |
| Curtis Lockshin Director | Sep 11, 2024 | Award | +2,000 | – | – | 2,000 |
| Patricia A. Bradford Director | Sep 11, 2024 | Award | +8,000 | – | – | 8,000 |
| Robert L. Ferrara Director | Sep 11, 2024 | Award | +10,000 | – | – | 10,000 |
| Robert M. Infarinato VP, Chief Financial Officer | Aug 13, 2024 | Award | +8,000 | – | – | 8,000 |
| Robert J. Bitterman President & CEO, Director | Jun 7, 2024 | Buy | +1,000 | $0.74 | $740 | 20,990 |
| Robert J. Bitterman President & CEO, Director | Jun 6, 2024 | Buy | +1,000 | $0.75 | $750 | 19,990 |
| Caitlin Kontulis Secretary & VP Finance & Admin | Mar 1, 2024 | Tax withholding | −335 | $0.96 | $322 | 10,643 |
| Robert J. Bitterman President & CEO, Director | Feb 26, 2024 | Buy | +2,500 | $0.91 | $2.28K | 18,990 |
| Robert J. Bitterman President & CEO, Director | Feb 20, 2024 | Tax withholding | −1,804 | $0.76 | $1.37K | 16,490 |
| Caitlin Kontulis Secretary & VP Finance & Admin | Feb 17, 2024 | Tax withholding | −523 | $0.66 | $345 | 10,978 |
| Caitlin Kontulis Secretary & VP Finance & Admin | Feb 15, 2024 | Tax withholding | −658 | $0.65 | $428 | 11,501 |
| Robert J. Bitterman President & CEO, Director | Oct 1, 2023 | Tax withholding | −917 | $1.51 | $1.38K | 18,294 |
| Robert J. Bitterman President & CEO, Director | Jul 1, 2023 | Buy | +1,000 | $2.84 | $2.84K | 19,211 |
| Robert J. Bitterman President & CEO, Director | Jun 30, 2023 | Buy | +1,000 | $2.88 | $2.88K | 18,211 |
| Robert L. Ferrara Director | Jun 14, 2023 | Buy | +2,000 | $3.10 | $6.20K | 6,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.83%
0M shares short
Days to cover
1.5
At 0M shares a day
Change since last report
-36.7%
From 0M shares
Short volume, 20 days
46.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Phio Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 35,939 shares on Sep 10, 2026 over the last 90 days.
See a number that looks wrong?